Clinical trial · Observational
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
NCT00303407CI-TRIAL-00000303terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nadroparin | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients in palliative care * Patients fully informed about their condition * Signed informed consent * No exclusion criteria Exclusion Criteria: * Absence of advanced cancer * Cancer previously cured * Venous thromboembolism diagnosed within 6 months prior to inclusion * Absence of discerning capacity * Active anti-thrombotic treatment with heparins or coumarines * Thrombocytopenia \<50G/l * PTT \>45sec * TP\<35% * Active bleeding * Renal failure \<20ml/min * Past history of heparin-induced thrombocytopenia
References
Publications (1)
- BACKGROUNDPrandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost. 1997 Jul;78(1):141-4. PMID 9198144